Quotient Sciences, a leading global drug development, research and manufacturing accelerator, and Intrepid Labs, the AI leader in pharmaceutical formulat...
BAY 3401016 is an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involve...
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to o...
Taiho Oncology Europe GmbH announced the UK launch of Lytgobi® (futibatinib), an irreversibly binding fibroblast growth factor receptor (FGFR) inhibi...
MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT0553...
Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life...
VANUDIS, a biotechnology startup developing the next generation of antibody-based therapeutics, has implemented Cenevo’s Labguru solution to scale ...
Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, announced that the first patient...
The point-of-care test delivers PCR-accurate results in just 15 minutes, enabling healthcare providers to act quickly and prevent severe complications ...
Bavarian Nordic A/S announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 month...
VNA-318, an oral brain-penetrant small molecule therapeutic modulates a novel target to reduce inflammation and improve mitochondrial function First-i...
The collaboration unites complementary scientific and technical expertise to provide seamless solutions across the biopharmaceutical value chain Clien...
First ever clinical evaluation of an in vivo HSC-directed gene insertion therapy aims to restore immune function for people living with X-linked chroni...
New name reflects company’s transformation as it advances toward the final phase of Lybrido™’s clinical development The Arletta but...
© 2025 Biopharma Boardroom. All Rights Reserved.
